Iovance Biotherapeutics, Inc. (LON:0JDK)

Market Cap	837.23M
Revenue (ttm)	186.30M +175.6%
Net Income	-295.82M
EPS	-0.89
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	65,008
Average Volume	138,399
Open	2.890
Previous Close	2.860
Day's Range	2.820 - 2.990
52-Week Range	1.570 - 6.495
Beta	0.77
RSI	61.32
Earnings Date	Feb 26, 2026

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It develops...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2007
• Employees: 838
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0JDK

Financial Performance

In 2024, Iovance Biotherapeutics's revenue was $164.07 million, an increase of 13698.99% compared to the previous year's $1.19 million. Losses were -$372.18 million, -16.18% less than in 2023.

Financial numbers in USD